O	0	7	Killing	Kill	VBG	B-VP
B-Cell	8	13	tumor	tumor	NN	B-NP
I-Cell	14	19	cells	cell	NNS	I-NP
O	20	27	through	through	IN	B-PP
O	28	33	their	their	PRP$	B-NP
B-Cellular_component	34	41	surface	surface	NN	I-NP
O	42	46	beta	beta	NN	I-NP
O	46	47	(	(	(	O
O	47	48	2	2	CD	B-NP
O	48	49	)	)	)	O
O	49	50	-	-	HYPH	B-NP
O	50	63	microglobulin	microglobulin	NN	I-NP
O	64	66	or	or	CC	O
O	67	72	major	major	JJ	B-NP
O	73	91	histocompatibility	histocompatibility	NN	I-NP
O	92	99	complex	complex	NN	I-NP
O	100	105	class	class	NN	I-NP
O	106	107	I	I	CD	B-NP
O	108	117	molecules	molecule	NNS	I-NP
O	117	118	.	.	.	O

O	120	128	Targeted	Target	VBN	B-NP
O	129	137	antibody	antibody	NN	I-NP
O	137	138	-	-	HYPH	O
O	138	143	based	base	VBN	B-NP
O	144	151	therapy	therapy	NN	I-NP
O	152	155	has	have	VBZ	B-VP
O	156	160	been	be	VBN	I-VP
O	161	165	used	use	VBN	I-VP
O	166	178	successfully	successfully	RB	B-ADVP
O	179	181	to	to	TO	B-VP
O	182	187	treat	treat	VB	I-VP
B-Cancer	188	195	cancers	cancer	NNS	B-NP
O	195	196	.	.	.	O

O	197	203	Recent	Recent	JJ	B-NP
O	204	211	studies	study	NNS	I-NP
O	212	216	have	have	VBP	B-VP
O	217	229	demonstrated	demonstrate	VBN	I-VP
O	230	234	that	that	IN	B-SBAR
B-Cell	235	240	tumor	tumor	NN	B-NP
I-Cell	241	246	cells	cell	NNS	I-NP
O	247	254	treated	treat	VBN	B-VP
O	255	259	with	with	IN	B-PP
O	260	270	antibodies	antibody	NNS	B-NP
O	271	279	specific	specific	JJ	B-ADJP
O	280	283	for	for	IN	B-PP
O	284	288	beta	beta	NN	B-NP
O	288	289	(	(	(	O
O	289	290	2	2	CD	B-NP
O	290	291	)	)	)	O
O	291	292	-	-	HYPH	O
O	292	305	microglobulin	microglobulin	NN	B-NP
O	306	307	(	(	(	O
O	307	311	beta	beta	NN	B-NP
O	311	312	(	(	(	B-LST
O	312	313	2	2	LS	I-LST
O	313	314	)	)	)	O
O	314	315	M	M	NN	B-NP
O	315	316	)	)	)	O
O	317	319	or	or	CC	O
O	320	325	major	major	JJ	B-NP
O	326	344	histocompatibility	histocompatibility	NN	I-NP
O	345	352	complex	complex	NN	I-NP
O	353	354	(	(	(	O
O	354	357	MHC	MHC	NN	B-NP
O	357	358	)	)	)	O
O	359	364	class	class	NN	B-NP
O	365	366	I	I	CD	B-NP
O	367	376	molecules	molecule	NNS	I-NP
O	377	384	undergo	undergo	VBP	B-VP
O	385	394	apoptosis	apoptosis	NN	B-NP
O	395	397	in	in	FW	B-ADVP
O	398	403	vitro	vitro	FW	I-ADVP
O	404	407	and	and	CC	O
O	408	410	in	in	FW	B-ADVP
O	411	415	vivo	vivo	FW	I-ADVP
O	416	417	(	(	(	O
O	417	422	mouse	mouse	NN	B-NP
O	423	429	models	model	NNS	I-NP
O	429	430	)	)	)	O
O	430	431	.	.	.	O

O	432	442	Antibodies	Antibody	NNS	B-NP
O	443	450	against	against	IN	B-PP
O	451	455	beta	beta	NN	B-NP
O	455	456	(	(	(	O
O	456	457	2	2	CD	B-NP
O	457	458	)	)	)	O
O	458	459	M	M	NN	B-NP
O	460	462	or	or	CC	I-NP
O	463	466	MHC	MHC	NN	I-NP
O	467	472	class	class	NN	I-NP
O	473	474	I	I	PRP	B-NP
O	475	481	induce	induce	VBP	B-VP
B-Cell	482	487	tumor	tumor	NN	B-NP
I-Cell	488	492	cell	cell	NN	I-NP
O	493	502	apoptosis	apoptosis	NN	I-NP
O	503	505	by	by	IN	B-PP
O	506	507	1	1	CD	B-NP
O	507	508	)	)	)	O
O	509	519	recruiting	recruit	VBG	B-VP
O	520	523	MHC	MHC	NN	B-NP
O	524	529	class	class	NN	I-NP
O	530	531	I	I	CD	B-NP
O	532	541	molecules	molecule	NNS	I-NP
O	542	544	to	to	TO	B-PP
B-Organism_substance	545	550	lipid	lipid	NN	B-NP
I-Organism_substance	551	556	rafts	raft	NNS	I-NP
O	557	560	and	and	CC	O
O	561	571	activating	activate	VBG	B-VP
O	572	575	LYN	LYN	NN	B-NP
O	576	582	kinase	kinase	NN	I-NP
O	583	586	and	and	CC	O
O	587	590	the	the	DT	B-NP
O	591	597	signal	signal	NN	I-NP
O	597	598	-	-	HYPH	O
O	598	609	transducing	transduce	VBG	B-VP
O	610	616	enzyme	enzyme	NN	B-NP
O	617	630	phospholipase	phospholipase	NN	I-NP
O	631	632	C	C	NN	I-NP
O	632	633	-	-	HYPH	B-NP
O	633	639	gamma2	gamma2	NN	I-NP
O	639	640	-	-	HYPH	O
O	640	649	dependent	dependent	JJ	B-NP
O	650	651	c	c	NN	I-NP
O	651	652	-	-	HYPH	B-NP
O	652	655	Jun	Jun	NN	I-NP
O	656	657	N	N	NN	I-NP
O	657	658	-	-	HYPH	B-NP
O	658	666	terminal	terminal	JJ	I-NP
O	667	673	kinase	kinase	NN	I-NP
O	674	683	signaling	signaling	NN	I-NP
O	684	691	pathway	pathway	NN	I-NP
O	692	695	and	and	CC	O
O	696	697	2	2	LS	B-LST
O	697	698	)	)	)	O
O	699	708	expelling	expel	VBG	B-VP
O	709	720	interleukin	interleukin	NN	B-NP
O	721	722	6	6	CD	I-NP
O	723	726	and	and	CC	I-NP
O	727	734	insulin	insulin	NN	I-NP
O	734	735	-	-	HYPH	B-NP
O	735	739	like	like	JJ	I-NP
O	740	746	growth	growth	NN	I-NP
O	747	753	factor	factor	NN	I-NP
O	754	755	1	1	CD	B-NP
O	756	765	receptors	receptor	NNS	I-NP
O	766	769	out	out	IN	B-PP
O	770	772	of	of	IN	B-PP
B-Organism_substance	773	778	lipid	lipid	NN	B-NP
I-Organism_substance	779	784	rafts	raft	NNS	I-NP
O	785	788	and	and	CC	O
O	789	799	inhibiting	inhibit	VBG	B-VP
O	800	803	the	the	DT	B-NP
O	804	810	growth	growth	NN	I-NP
O	811	814	and	and	CC	I-NP
O	815	823	survival	survival	NN	I-NP
O	824	830	factor	factor	NN	I-NP
O	830	831	-	-	HYPH	B-NP
O	831	838	induced	induce	VBN	I-NP
O	839	849	activation	activation	NN	I-NP
O	850	852	of	of	IN	B-PP
O	853	856	the	the	DT	B-NP
O	857	877	phosphatidylinositol	phosphatidylinositol	NN	I-NP
O	878	879	3	3	CD	I-NP
O	879	880	-	-	HYPH	I-NP
O	880	886	kinase	kinase	NN	I-NP
O	886	887	/	/	SYM	B-NP
O	887	890	Akt	Akt	NN	I-NP
O	891	894	and	and	CC	O
O	895	908	extracellular	extracellular	JJ	B-NP
O	909	915	signal	signal	NN	I-NP
O	915	916	-	-	HYPH	B-NP
O	916	923	related	relate	VBN	I-NP
O	924	930	kinase	kinase	NN	I-NP
O	931	939	pathways	pathway	NNS	I-NP
O	939	940	.	.	.	O

O	941	953	Consequently	Consequently	RB	B-ADVP
O	953	954	,	,	,	O
B-Cellular_component	955	968	mitochondrial	mitochondrial	JJ	B-NP
O	969	978	integrity	integrity	NN	I-NP
O	979	981	is	be	VBZ	B-VP
O	982	993	compromised	compromise	VBN	I-VP
O	993	994	,	,	,	O
O	995	998	and	and	CC	O
O	999	1002	the	the	DT	B-NP
O	1003	1010	caspase	caspase	NN	I-NP
O	1010	1011	-	-	HYPH	B-NP
O	1011	1012	9	9	CD	I-NP
O	1012	1013	-	-	HYPH	I-NP
O	1013	1022	dependent	dependent	JJ	I-NP
O	1023	1030	cascade	cascade	NN	I-NP
O	1031	1033	is	be	VBZ	B-VP
O	1034	1043	activated	activate	VBN	I-VP
O	1044	1046	in	in	IN	B-PP
O	1047	1054	treated	treat	VBN	B-NP
B-Cell	1055	1060	tumor	tumor	NN	I-NP
I-Cell	1061	1066	cells	cell	NNS	I-NP
O	1066	1067	.	.	.	O

O	1068	1075	However	However	RB	B-ADVP
O	1075	1076	,	,	,	O
O	1077	1085	although	although	IN	B-SBAR
O	1086	1090	beta	beta	NN	B-NP
O	1090	1091	(	(	(	O
O	1091	1092	2	2	CD	B-NP
O	1092	1093	)	)	)	O
O	1093	1094	M	M	NN	B-NP
O	1095	1098	and	and	CC	I-NP
O	1099	1102	MHC	MHC	NN	I-NP
O	1103	1108	class	class	NN	I-NP
O	1109	1110	I	I	PRP	B-NP
O	1111	1114	are	be	VBP	B-VP
O	1115	1124	expressed	express	VBN	I-VP
O	1125	1127	on	on	IN	B-PP
O	1128	1134	normal	normal	JJ	B-NP
B-Cell	1135	1148	hematopoietic	hematopoietic	JJ	I-NP
I-Cell	1149	1154	cells	cell	NNS	I-NP
O	1154	1155	,	,	,	O
O	1156	1161	which	which	WDT	B-NP
O	1162	1164	is	be	VBZ	B-VP
O	1165	1166	a	a	DT	B-NP
O	1167	1176	potential	potential	JJ	I-NP
O	1177	1183	safety	safety	NN	I-NP
O	1184	1191	concern	concern	NN	I-NP
O	1191	1192	,	,	,	O
O	1193	1196	the	the	DT	B-NP
O	1197	1207	monoclonal	monoclonal	JJ	I-NP
O	1208	1218	antibodies	antibody	NNS	I-NP
O	1219	1223	were	be	VBD	B-VP
O	1224	1233	selective	selective	JJ	B-ADJP
O	1234	1236	to	to	TO	B-PP
B-Cell	1237	1242	tumor	tumor	NN	B-NP
I-Cell	1243	1248	cells	cell	NNS	I-NP
O	1249	1252	and	and	CC	O
O	1253	1256	did	do	VBD	B-VP
O	1257	1260	not	not	RB	I-VP
O	1261	1267	damage	damage	VB	I-VP
O	1268	1274	normal	normal	JJ	B-NP
B-Cell	1275	1280	cells	cell	NNS	I-NP
O	1281	1283	in	in	FW	B-ADVP
O	1284	1289	vitro	vitro	FW	I-ADVP
O	1290	1292	or	or	CC	O
O	1293	1295	in	in	IN	B-PP
O	1296	1301	human	human	JJ	B-NP
O	1301	1302	-	-	HYPH	I-NP
O	1302	1306	like	like	JJ	I-NP
O	1307	1312	mouse	mouse	NN	I-NP
O	1313	1319	models	model	NNS	I-NP
O	1319	1320	.	.	.	O

O	1321	1326	These	These	DT	B-NP
O	1327	1335	findings	finding	NNS	I-NP
O	1336	1343	suggest	suggest	VBP	B-VP
O	1344	1348	that	that	IN	B-SBAR
O	1349	1358	targeting	target	VBG	B-VP
O	1359	1363	beta	beta	NN	B-NP
O	1363	1364	(	(	(	B-LST
O	1364	1365	2	2	LS	I-LST
O	1365	1366	)	)	)	O
O	1366	1367	M	M	NN	B-NP
O	1368	1370	or	or	CC	I-NP
O	1371	1374	MHC	MHC	NN	I-NP
O	1375	1380	class	class	NN	I-NP
O	1381	1382	I	I	CD	I-NP
O	1383	1385	by	by	IN	B-PP
O	1386	1391	using	use	VBG	B-VP
O	1392	1402	antibodies	antibody	NNS	B-NP
O	1403	1405	or	or	CC	O
O	1406	1411	other	other	JJ	B-NP
O	1412	1418	agents	agent	NNS	I-NP
O	1419	1425	offers	offer	VBZ	B-VP
O	1426	1427	a	a	DT	B-NP
O	1428	1437	potential	potential	JJ	I-NP
O	1438	1449	therapeutic	therapeutic	JJ	I-NP
O	1450	1458	approach	approach	NN	I-NP
O	1459	1462	for	for	IN	B-PP
O	1463	1467	beta	beta	NN	B-NP
O	1467	1468	(	(	(	O
O	1468	1469	2	2	CD	B-NP
O	1469	1470	)	)	)	O
O	1470	1471	M	M	NN	B-NP
O	1471	1472	/	/	SYM	O
O	1472	1475	MHC	MHC	NN	B-NP
O	1476	1481	class	class	NN	I-NP
O	1482	1483	I	I	CD	I-NP
O	1483	1484	-	-	HYPH	O
O	1484	1494	expressing	express	VBG	B-VP
B-Cancer	1495	1507	malignancies	malignancy	NNS	B-NP
O	1507	1508	.	.	.	O

O	1509	1515	Cancer	Cancer	NNP	B-NP
O	1516	1520	2010	2010	CD	I-NP
O	1520	1521	.	.	.	O

O	1522	1523	(	(	(	O
O	1523	1524	c	c	NN	B-NP
O	1524	1525	)	)	)	O
O	1526	1530	2010	2010	CD	B-NP
O	1531	1539	American	American	NNP	I-NP
O	1540	1546	Cancer	Cancer	NNP	I-NP
O	1547	1554	Society	Society	NNP	I-NP
O	1554	1555	.	.	.	O

